New Trial Shows Drugs are Effective for Diabetic Macular Edema

 Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy.  Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.  Over the past few…

Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research

Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research.  The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and…

Spark Surges in IPO as Prices Fuel Gene Therapy

Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug.  The treatments focus on diseases where a single mutation in the genetic code is known to be…

Eleven Biotherapeutics Completes Enrollment of EBI-005 in Patients with Dry Eye Disease

Eleven Biotherapeutics (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven’s lead drug candidate in development…

RetroSense Granted Orphan Drug Designation for Retinitis Pigmentosa

RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in…

Lab-Grown Retina from Stem Cells Responds to Light

…stem cell researchers have struggled to coax the malleable cells to form the 10 layers of the retina. And, crucially, no one had, before now, produced lab-grown retinal cells that they demonstrated would respond to light.Researchers at Johns Hopkins pulled it off, they reported in a paper published recently in Nature Communications. They cultivated a…

Smartphones become ‘eye-phones’ with low-cost devices developed by ophthalmologists

Researchers at the Stanford University School of Medicine have developed two inexpensive adapters that enable a smartphone to capture high-quality images of the front and back of the eye. The adapters make it easy for anyone with minimal training to take a picture of the eye and share it securely with other health practitioners or…

eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference

The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…

Retinal Ischemia Tied to Variant of Acute Macular Neuroretinopathy

Paracentral acute middle maculopathy is a newly identified variant of acute macular neuroretinopathy that appears to result from retinal capillary ischemia, according to a retrospective observational case series. “This has been traditionally a very rare disease but now with advanced retinal imaging systems such as spectral domain optical coherence tomography (SD-OCT) and infrared reflectance imaging…